摘要
目的 评价东菱克栓酶治疗急性脑梗死的临床效果及其安全性。 方法 98例脑梗死患者随机分为东菱克栓酶治疗组 (三天连续疗法 )和低分子右旋糖酐 +丹参 +胞二磷胆碱对照组。 结果 治疗组治疗后起效快 ,14天总有效率达 88%,明显优于对照组。治疗组降低血纤维蛋白原水平显著 ,不良反应轻微。 结论 东菱克栓酶治疗急性脑梗死疗效肯定 ,而且比较安全。
Objective To evaluate the therapeutic effect and safety of batroxobin(DF-521) in acute ischemic stroke(ACI). Methods 98 patients with ACI were randomly divided into DF-521 treating group and control group with the routine treatment. Results The effect was created rapidly in DF-521 group,the total effective rate was 88% in 14 day after treating.There was significant difference in DF-521 group and control group.The capacity of fibrinogen in plasma was decreased significantly in DF-521 group,the adverse effect was little. Conclusion The DF-521 should be an effective remedy for ACI,and safe,too.
出处
《实用心脑肺血管病杂志》
2003年第5期267-268,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
